Insider Transactions in Q1 2021 at Bei Gene, Ltd. (BGNE)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-49.34%
|
$486,000
$324.25 P/Share
|
|
Mar 29
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Mar 12
2021
|
Donald W. Glazer Director |
SELL
Bona fide gift
|
Direct |
80,000
-2.75%
|
-
|
|
Feb 26
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-35.38%
|
$478,500
$319.27 P/Share
|
|
Feb 26
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Jan 29
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-33.68%
|
$486,000
$324.17 P/Share
|
|
Jan 29
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Jan 15
2021
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
12,600
-77.75%
|
$4,334,400
$344.96 P/Share
|
|
Jan 15
2021
|
Howard Liang CFO & Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,600
+50.0%
|
$75,600
$6.5 P/Share
|
|
Jan 14
2021
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,400
-89.29%
|
$481,600
$344.71 P/Share
|
|
Jan 14
2021
|
Howard Liang CFO & Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,400
+50.0%
|
$8,400
$6.5 P/Share
|
|
Jan 04
2021
|
Baker Bros. Advisors LP |
SELL
Open market or private sale
|
Indirect |
121,154
-1.03%
|
$26,653,880
$220.5 P/Share
|